A number of investment brokers have recently updated their price targets on shares of Calithera Biosciences, Inc. (NASDAQ:CALA).

Most recent broker ratings

03/09/2016 – Calithera Biosciences, Inc. had its “market outperform” rating reiterated by analysts at JP Morgan. They now have a USD 12 price target on the stock.

11/10/2015 – Calithera Biosciences, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 13 price target on the stock.

07/24/2015 – Citigroup began new coverage on Calithera Biosciences, Inc. giving the company a “buy” rating. They now have a USD 11 price target on the stock.

05/01/2015 – Calithera Biosciences, Inc. was upgraded to “hold” by analysts at Zacks.

10/27/2014 – JMP Securities began new coverage on Calithera Biosciences, Inc. giving the company a “outperform” rating. They now have a USD 20 price target on the stock.

10/27/2014 – Wells Fargo began new coverage on Calithera Biosciences, Inc. giving the company a “outperform” rating. They now have a USD 19.5 price target on the stock.

The share price of Calithera Biosciences, Inc. (NASDAQ:CALA) was up +1.11% during the last trading session, with a day high of 4.61. 47840 shares were traded on Calithera Biosciences, Inc.’s last session.

The stock’s 50 day moving average is 5.57 and its 200 day moving average is 6.35. The stock’s market capitalization is 82.51M. Calithera Biosciences, Inc. has a 52-week low of 4.31 and a 52-week high of 14.75.

View other investors thoughts on Calithera Biosciences, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.